View clinical trials related to General Movement Assessment.
Filter by:In course of the SafeBoosC III trial, we would like to analyse routinely performed GMA as secondary outcome parameter in an ancillary observational study. First aim is to analyse in surviving neonates included into the SafeboosC III trial any differences between the experimental group group and control group in Global-GMA at term age. Second aim is to investigate GMOS at term age and if available GMA at 9-16 weeks corrected age.